Farnesyl protein transferase: A review of structural studies

Current Opinion in Drug Discovery and Development

Volumn 2, Issue 5, 1999, Pages 475-483

  Strickland, Corey L ^a   Weber, Patricia C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cancer; Farnesyl; Geranylgeranyl; Ras protein; Transferase

Indexed keywords

4 [2 [4 [3,10 DIBROMO 8 CHLORO 6,11 DIHYDRO 5H BENZO(5,6) CYCLOHEPTA[1,2 B]PYRIDIN 11 YL] 1 PIPERIDINYL] 2 OXOETHYL] 1 PIPERIDINECARBOXAMIDE; ARGLABIN; GB 02323842; GERANYLTRANSFERASE; L 778123; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; TIPIFARNIB; UNCLASSIFIED DRUG; US 05854264; WO 09511917; WO 09702817; WO 09703050; WO 09705902; WO 09726246; WO 09740006; WO 09749700; WO 09807692; WO 09817629; WO 09848789; WO 09850030; WO 09906376; WO 09918951;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER INHIBITION; CLINICAL TRIAL; DRUG BINDING SITE; ENZYME ACTIVE SITE; ENZYME INHIBITOR INTERACTION; ENZYME MECHANISM; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PHASE 2 CLINICAL TRIAL; PROTEIN SECONDARY STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0032694151     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Barbacid M: Ras genes. Annu Rev Biochem (1987) 56:779-827.
2. Oliff A: Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Biochim Biophys Acta (1999) 1423(3):C19-30.
3. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB: Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science (1993) 260(5116):1934-1937.
4. James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, Marsters JC Jr: Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells. Science (1993) 260(5116):! 937-1942.
5. Leonard DM: Ras farnesyltransferase: a new therapeutic target. J Med Chem (1997) 40(19):2971-2990.
6. Casey PJ, Seabra MC: Protein prenyltransferases. J Biol Chem (1996) 271(10):5289-5292.
7. Long SB, Casey PJ, Beese LS: Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate. B/oc/7em/sfn/(1998) 37(27):9612-9618.
8. Dunten P, Kammlott U, Crowther R, Weber D, Palermo R, Birktoft J: Protein farnesyltransferase: structure and implications for substrate binding. Biochemistry (1998)37(22):7907-7912.
9. Park HW, Boduluri SR, Moomaw JF, Casey PJ, Beese LS: Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution [published erratum appears in Science (1997) 276(5309):21].
10. Science (1997) 275(5307): 1800-1804. •• The first structure of FPT at 2.25 Ais reported.
11. Strickland CL, Windsor WT, Syto R, Wang L, Bond R, Wu Z, Schwarte J, Le HV, Beese LS, Weber PC: Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. Biochemistry (1998) 37(47):16601 -16611. •• The ternary complex of FPT with aHFP and a CaaX peptide is described.
12. Strickland CL, Weber PC, Windsor WT, Wu Z, Le HV, Albanese MM, Alvarez CS, Cesarz D, del Rosario J, Deskus J, Mallams AK, Njoroge FG, Piwinski JJ, Remiszewski S, Rossman RR, Taveras AG, Vibulbhan B, Doll RJ, Girijavallabhan VM, Ganguly AK: Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships. J Med Chem (1999) 42(12):2125-2135. •• This paper presents the first structure of an inhibitor bound-to FPT. Crystallographic data are also correlated with thermodynamlb. binding parameters.
13. Feng XH, Kung SD: Unique sequence repeats in the alphasubunit of protein farnesyltransferases. Trends Biochem Sei (1993)18(11):426-427.
14. Murzin AG, Brenner SE, Hubbard T, Chothia C: SCOP: A structural classification of proteins database for the investigation of sequences and structures. J Mol Bio! (1995)247(4):536-540.
15. Janin J, Miller S, Chothia C: Surface, subunit Interfaces and interior of oligomeric proteins. J Mol Biol (1988) 204(1 ):155-164.
16. Fu HW, Beese LS, Casey PJ: Kinetic analysis of zinc ligand mutants of mammalian protein farnesyltransferase. Biochemistry (1998) 37(13):4465-4472.
17. Hightower KE, Fierke CA: Zinc-catalyzed sulfur alkyation: Insights from protein farnesyltransferase. Curr Opin Chem B/o/(1999)3(2):176-181.
18. Lebowitz PF, Prendergast GC: Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho. Oncogene (1998)17(11):1439-1445.
19. Cox AD, Der CJ: Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras? Biochim Biophys Acta (1997)1333(1):F51-71.
20. Lowy DR, Willumsen BM: Function and regulation of ras. Annu Rev Biochem (1993) 62:851-891.
21. Pai EF, Krengel U, Petsko GA, Goody RS, Kabsch W, Wittinghofer A: Refined crystal structure of the triphosphate conformation of H-Ras p21 at 1.35 angstroms resolution: Implications for the mechanism of GTP hydrolysis. EMBO J(1990) 9(8):2351-2359.
22. Hancock JF, Magee AI, Childs JE, Marshall CJ: All ras proteins are polyisoprenylated but only some are palmitoylated. Ce//(1989) 57(7): 1167-1177.
23. Casey PJ, Solski PA, Der CJ, Buss JE: p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sei USA (1989) 86(21 ):8323-8327.
24. Gutierrez L, Magee AI, Marshall CJ, Hancock JF: Posttranslational processing of p21ras is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis. EMBO J(1989) 8(4):1093-1098.
25. Ciarke S, Vogel JP, Deschenes RJ, Stock J: Posttranslational modification of the Ha-ras oncogene protein: evidence for a third class of protein carboxyl methyltransferases [published erratum appears in Proc Natl Acad Sei USA (1988) 85(20):7556].
26. Proc Natl Acad Sei USA (1988) 85(13):4643-4647.
27. Reiss Y, Stradley SJ, Gierasch LM, Brown MS, Goldstein JL: Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase. Proc Natl Acad Sei USA (1991)88(3):732-736.
28. Goldstein JL, Brown MS, Stradley SJ, Reiss Y, Gierasch LM: Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase. JBiol Chem (1991) 266(24):15575-15578.
29. Zhang FL, Kirschmeier P, Carr D, James L, Bond RW. Wang L, Patton R, Windsor WT, Syto R, Zhang R, Bishop WR: Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as In vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem (1997) 272(15):10232-10239.
30. James GL, Goldstein JL, Brown MS: Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and y confer resistance to benzodiazepine peptidomimetic in } vitro. J Biol Chem (1995) 270(11 ):6221 -6226.
31. Stradley SJ, Rizo J, Gierasch LM: Conformation of a heptapeptide substrate bound to protein farnesyltransferase. /oc/jem/sf;y(1993) 32(47):12586-12590.
32. Koblan KS, Culberson JC, Desolms SJ, Giuliani EA, Mosser SD, Omer CA, Pitzenberger SM, Bogusky MJ: NMR studies of novel inhibitors bound to farnesyl-protein transferase. Protein Sc/(1995) 4(4):681-688.
33. Armstrong SA, Seabra MC, Sudhof TC, Goldstein JL, Brown MS: cDNA cloning and expression of the alpha and beta subunits of rat Rab geranylgeranyl transferase. J Biol Chem (1993) 268(16):12221-12229.
34. Seabra MC, Reiss Y, Casey PJ, Brown MS, Goldstein JL: Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit Cell (1991) 65(3):429-434.
35. Zhang FL, Diehl RE, Kohl NE, Gibbs JB, Giros B, Casey PJ, Omer CA: cDNA cloning and expression of rat and human protein geranylgeranyitransferase type-l. J Biol Chem (1994) 269(5):3175-3180.
36. Zhang FL, Casey PJ: Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem (1996) 65:241-269.
37. Gibbs JB, Oliff A: The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol (1997) 37:143-166. • A review of FPT inhibitors.
38. Rotella DP: An update on COX-2 and farnesyltransferase inhibitor development. Curr Opin Drug Discov Dev (1998) 1(2):165-174. • A review of FPT inhibitors.
39. Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielsen L, Prioli N, Dell J, Sinha D, Syed J, Korfmacher WA, Nomeir AA, Lin CC, Wang L, Taveras AG, Doll RJ, Njoroge FG, Mallams AK, Remiszewski S, Catino JJ, Girijavallabhan VM, Kirschmeier P, Bishop WR: Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res (1998) 58(21 ):4947-4956.
40. Njoroge FG, Taveras AG, Kelly J, Remiszewski S, Mallams AK, Wolin R, Afonso A, Cooper AB, Rane DF, Liu Y, Wong J, Vibulbhan B, Pinto P, Deskus J, Alvarez CS, del Rosario J, Connolly M, Wang J, Desai J, Rossman RR, Bishop WR, Patton R, Wang L, Kirschmeier P, Bryant MS, Nomeir AA, Lin C, Liu M, McPhail AT, Doll RJ, Girijavallabhan VM, Ganguly AK: (+)-4-[2-[4-{8-Chloro-3,10-dibromo-6,11 -dihydro-5Hbenzo[5,6]cyclohepta[1,2-£>]-pyridin-11 (R)-y l)-1 -piperidinyl]-2-oxo-ethyl]-1-piperidine-carboxamide (SCH-66336): A very potent farnesyl protein transferase inhibitor as a novel antitumor agent. J Med Chem (1998) 41(24):48904902.